



TIME	PRESENTATION TITLE	SPEAKER
7:15 am	Registration Opens   Hot Breakfast Available	
8:10 am	Welcome & Opening Remarks <ul style="list-style-type: none"> <li>◦ <b>Derek Thompson – Čaabat' Bookwilla</b>, Director, Indigenous Engagement, UBC Faculty of Medicine</li> <li>◦ <b>Lakshmi Yatham</b>, MBBS, FRCPC, MRCPsych (UK), Head, Department of Psychiatry, UBC</li> <li>◦ <b>Randall White</b>, MD, FRCPC, PPPC 2024 Scientific Committee Co-Chair</li> </ul>	
8:30 am	<b>Current Hot Topics in Psychopharmacological and Psychotherapeutic Treatment of Schizophrenia</b> <i>(In-person &amp; Livestreamed) — Harbourfront Ballroom</i> <ul style="list-style-type: none"> <li>• Assess the efficacy and tolerability of existing antipsychotics for schizophrenia</li> <li>• Examine new findings on dosing, patient subgroups, switching and other clinically relevant topics in the treatment of schizophrenia</li> <li>• Review the most effective psychotherapeutic &amp; psychosocial interventions for schizophrenia</li> </ul>	 <b>Stefan Leucht, MD</b> <i>Head, Section for Evidence-Based Medicine in Psychiatry and Psychotherapy, Department of Psychiatry and Psychotherapy, Technical University of Munich, Germany (TUM)</i>
9:15 am	<b>Deprescribing Antidepressants</b> <i>(In-person &amp; Livestreamed) — Harbourfront Ballroom</i> <ul style="list-style-type: none"> <li>• Examine the risks associated with long-term use of antidepressants and the benefits of systematic deprescribing</li> <li>• Describe the concept of hyperbolic tapering and why it is crucial for minimizing withdrawal symptoms and ensuring patient safety during the deprescribing process</li> <li>• Review the step-by-step deprescribing process for safely reducing and discontinuing antidepressants</li> </ul>	 <b>David Taylor, MSc, PhD, FFRPS, FRCP, FRPharmS</b> <i>Director of Pharmacy and Pathology, Maudsley Hospital; Professor of Psychopharmacology, King's College, London</i>  <i>*Prof. Taylor is delivering this lecture virtually from London, UK.</i>
10:00 am	15-MIN REFRESHMENT BREAK	
10:15 am	<b>Heart-Brain Connections in Relation to Youth Bipolar Disorder: Is it Time to Take Clinical Action?</b> <i>(In-person &amp; Livestreamed) — Harbourfront Ballroom</i> <ul style="list-style-type: none"> <li>• Identify factors underlying elevated cardiovascular risk in bipolar disorder</li> <li>• Recognize the relevance of vascular metrics to brain structure and function, and psychiatric symptoms</li> <li>• Consider the advantages of integrating heart health in the management and conceptualization of bipolar disorder</li> </ul>	 <b>Benjamin Goldstein, MD, PhD, FRCPC</b> <i>RBC Investments Chair in Children's Mental Health &amp; Developmental Psychopathology; Director, Centre for Youth Bipolar Disorder Centre for Addiction and Mental Health</i>  <i>*Dr. Goldstein is delivering this lecture virtually from Toronto, ON.</i>
11:00 am	<b>Canadian Guidelines for the Assessment and Treatment of Anxiety in Older Adults</b> <i>(In-person &amp; Livestreamed) — Harbourfront Ballroom</i> <ul style="list-style-type: none"> <li>• Review key risk factors for anxiety in older adults</li> <li>• Discuss recommendations for assessment and diagnosis of anxiety in older adults</li> <li>• Identify evidence-based treatments for anxiety in older adults</li> </ul>	 <b>Andrea Iaboni, MD, DPhil, FRCPC</b> <i>Geriatric Psychiatrist and Medical Lead, Senior Mental Health, University Health Network; Senior Scientist, KITE Research Institute, Toronto Rehab, UHN; Associate Professor, Dept of Psychiatry, University of Toronto</i>
11:45 am	75-MIN LUNCH BREAK	
1:00 pm	<b>CONCURRENT SESSION 1:</b>	
	<b>1A) The Simple Things You Need to Know to Interpret Meta-Analysis</b> <i>(In-person Only / Recorded) — Port of Vancouver</i> <ul style="list-style-type: none"> <li>• Identify and describe the key components of a meta-analysis</li> <li>• Learn to read and interpret forest plots to effectively draw conclusions about the results of multiple studies</li> <li>• Review advanced meta-analytic methods, including meta-regression, publication bias assessment, and subgroup analysis</li> </ul>	 <b>Stefan Leucht, MD</b> <i>Head, Section for Evidence-Based Medicine in Psychiatry and Psychotherapy, Department of Psychiatry and Psychotherapy, Technical University of Munich, Germany (TUM)</i>
	<b>1B) How to Manage the Cannabis-Using Patient with Psychosis</b> <i>(In-person &amp; Livestreamed) — Ballroom 2/3</i> <ul style="list-style-type: none"> <li>• Understand the relationship between cannabis use and psychosis</li> <li>• Distinguish primary psychoses from cannabis induced psychoses</li> <li>• Implement appropriate pharmacological and psychosocial interventions for co-morbid cannabis use and psychotic disorders</li> </ul>	 <b>David Crockford, MD, FRCPC, DRCPC(AM), DABPN, CCSAM, DLFAPA, DFAPA</b> <i>Clinical Professor, University of Calgary, Department of Psychiatry; Clinical Medical Director, Early Psychosis Intervention Program</i>

# Agenda

FRIDAY, September 20, 2024



TIME	PRESENTATION TITLE	SPEAKER
	<b>1C) rTMS for Treatment Resistant Depression</b> <i>(In-person &amp; Livestreamed) — Ballroom 1</i> <ul style="list-style-type: none"><li>Acquire an understanding of the principles and mechanisms for treating depression with rTMS</li><li>Distinguish suitable candidates for rTMS based on indications and contraindications</li><li>Describe how rTMS is positioned in the algorithm for treating depression as monotherapy or as an adjunct to other treatments</li></ul>	 <b>Peter Chan, MD, FRCPC, D.ISAM</b> <i>Geriatric, Consultation-Liaison and Addiction Psychiatrist, Vancouver General Hospital; Head of Neurostimulation Program, VGH; Clinical Professor, Dept. of Psychiatry, UBC</i>
1:45 pm	15-MIN REFRESHMENT BREAK	
2:00 pm	<b>CONCURRENT SESSION 2:</b>	
	<b>2A) Lived Experience Session: Anxiety, Psychosis and Us — A dialogue between a psychiatric care giver and a family that sought care</b> <i>(In-person Only / Recorded) — Port of Vancouver</i> <ul style="list-style-type: none"><li>Gain insights into challenges faced by youth, young adults and their families who seek mental health care</li><li>Reflect on strategies to mitigate barriers to community care for people with mental health needs</li><li>Understand stigma and psychological impacts on patients and their families when a youth receives a psychiatric diagnosis and requires medication</li></ul>	 <b>Kam Keramatian, MD, MSc, FRCPC</b> <i>Assistant Professor, Department of Psychiatry, University of British Columbia</i>  <b>Alexander Girling</b>  <b>Brenda Sawatzky-Girling</b>
	<b>2B) Impact of Antidepressants on Cognitive Functioning in Late-Life Depression</b> <i>(In-person &amp; Livestreamed) — Ballroom 1</i> <ul style="list-style-type: none"><li>Describe patterns of cognitive deficits that are commonly present in late-life depression (LLD)</li><li>Recognize cognitive deficits that are more or less likely to improve with pharmacotherapy of LLD</li><li>Discuss the impact of medication selection and cognitive phenotype on LLD outcomes</li></ul>	 <b>Nicholas Ainsworth, MD, FRCPC</b> <i>Geriatric Psychiatrist, Providence Health Care; Marshall Fellow, Institute of Mental Health, UBC; President-Elect, BC Psychiatric Association</i>
	<b>2C) Current Trends in Canada's Illicit Drug Market: An Exploration of the Rapidly Changing Drug Situation</b> <i>(In-person &amp; Livestreamed) — Ballroom 2/3</i> <ul style="list-style-type: none"><li>Name the controlled substances that are currently dominating the illicit drug market</li><li>Name the most commonly detected cutting agents or adulterants being added to illicit substances, and recognize the role of these agents in the drug trade</li><li>Explain the role of Organized Crime Groups in importing, producing and distributing illicit substances</li></ul>	 <b>Conor King</b> <i>Inspector, Victoria Police Department</i>  <i>Moderated by <b>Nick Mathew, MD, ABPN, FRCPC, ABPM</b>, Medical Director, Complex Mental Health and Substance Use Services, PHSA</i>
2:45 pm	15-MIN REFRESHMENT BREAK	
3:00 pm	<b>Treating Alcohol Use Disorder and Comorbid Depression or Anxiety</b> <i>(In-person &amp; Livestreamed) — Harbourfront Ballroom</i> <ul style="list-style-type: none"><li>Recognize the frequent prevalence of comorbid depression or anxiety with alcohol use disorder</li><li>Differentiate alcohol induced depression or anxiety from underlying primary major depressive or anxiety disorders</li><li>Appropriately utilize antidepressant medications in persons with alcohol use disorders with comorbid major depressive or anxiety disorders</li></ul>	 <b>David Crockford, MD, FRCPC, DRCPC(AM), DABPN, CCSAM, DLFAPA, DFCPA</b> <i>Clinical Professor, University of Calgary, Department of Psychiatry; Clinical Medical Director, Early Psychosis Intervention Program</i>
3:45 pm	Closing Remarks   Conference Ends  <i>Thank you for joining us!</i> <i>Please complete the online evaluation form before you depart:</i> 	<b>Reza Rafizadeh, BScPharm, ACPR, PhD</b> <i>Clinical Pharmacy Specialist, BC Mental Health and Substance Use Services; PPPC 2024 Scientific Committee Co-Chair</i>